NOVAVAX, INC. |
Market Closed -
Other stock markets
|
After market 19:56:56 | |||
| 13.11 USD | +47.64% |
|
13.02 | -0.65% |
| 05-13 | Novavax Shares Pop Another 50% Following Sanofi Deal | DJ |
| 05-13 | Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank... |  |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 952M 1.3B | Sales 2025 * | 586M 801M | Capitalization | 1.84B 2.52B |
|---|---|---|---|---|---|
| Net income 2024 * | 18M 24.62M | Net income 2025 * | -116M -159M | EV / Sales 2024 * | 1.05 x |
| Net cash position 2024 * | 837M 1.15B | Net cash position 2025 * | 704M 963M | EV / Sales 2025 * | 1.94 x |
| P/E ratio 2024 * |
206
x | P/E ratio 2025 * |
-23.8
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | -0.65% | ||
| 1 week | +175.42% | ||
| Current month | +202.77% | ||
| 1 month | +206.31% | ||
| 3 months | +236.15% | ||
| 6 months | +109.09% | ||
| Current year | +173.12% |
1 week
4.43
13.97
1 month
3.8113.97
Current year
3.5313.97
1 year
3.5313.97
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 17 M€ | +6.46% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 13.11 | +47.64% | 123,301,079 |
| 24-05-10 | 8.88 | +98.66% | 170,871,994 |
| 24-05-09 | 4.47 | 0.00% | 4,533,199 |
| 24-05-08 | 4.47 | -3.04% | 3,080,374 |
| 24-05-07 | 4.61 | -3.15% | 5,271,344 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.11
USD
Average target price
19.75
USD
Spread / Average Target
+50.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +173.12% | 1.84B | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +46.00% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- NVAX Stock
